Renalytix Plc
RENXF
$0.02
-$0.01-35.66%
OTC PK
| 12/31/2025 | 09/30/2025 | 12/31/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.83% | 53.26% | 9.73% | -26.10% | -40.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.83% | 53.26% | 9.73% | -26.10% | -40.52% |
| Cost of Revenue | 5.82% | -5.21% | -21.25% | -0.33% | -32.49% |
| Gross Profit | 0.00% | 300.00% | 74.67% | -154.55% | -52.39% |
| SG&A Expenses | -14.85% | 10.02% | -21.53% | -45.68% | -21.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.88% | -6.81% | -55.93% | -42.69% | -16.62% |
| Operating Income | -9.10% | 14.47% | 61.51% | 43.79% | 13.67% |
| Income Before Tax | -4.54% | 14.30% | 54.32% | 36.05% | 18.80% |
| Income Tax Expenses | -- | -- | -150.00% | -- | -- |
| Earnings from Continuing Operations | -4.60% | 14.34% | 54.37% | 36.04% | 18.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.60% | 14.34% | 54.37% | 36.04% | 18.76% |
| EBIT | -9.10% | 14.47% | 61.51% | 43.79% | 13.67% |
| EBITDA | -- | -- | 61.74% | 43.76% | 13.28% |
| EPS Basic | 41.44% | 76.29% | 79.24% | 43.96% | 37.49% |
| Normalized Basic EPS | 45.30% | 73.11% | 77.97% | 51.86% | 34.12% |
| EPS Diluted | 41.44% | 76.29% | 79.89% | 43.46% | 35.71% |
| Normalized Diluted EPS | 45.30% | 73.11% | 77.97% | 51.86% | 34.12% |
| Average Basic Shares Outstanding | 79.28% | 261.89% | 119.35% | 14.14% | 29.88% |
| Average Diluted Shares Outstanding | 79.28% | 261.89% | 119.35% | 14.14% | 29.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |